Tyra Biosciences, Inc. (TYRA): Price and Financial Metrics


Tyra Biosciences, Inc. (TYRA): $16.07

0.37 (+2.36%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add TYRA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

TYRA Stock Price Chart Interactive Chart >

Price chart for TYRA

TYRA Price/Volume Stats

Current price $16.07 52-week high $16.86
Prev. close $15.70 52-week low $4.93
Day low $15.73 Volume 28,100
Day high $16.86 Avg. volume 54,582
50-day MA $12.95 Dividend yield N/A
200-day MA $9.20 Market Cap 681.95M

Tyra Biosciences, Inc. (TYRA) Company Bio


Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2-related cancers, FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.


TYRA Latest News Stream


Event/Time News Detail
Loading, please wait...

TYRA Latest Social Stream


Loading social stream, please wait...

View Full TYRA Social Stream

Latest TYRA News From Around the Web

Below are the latest news stories about TYRA BIOSCIENCES INC that investors may wish to consider to help them evaluate TYRA as an investment opportunity.

Tyra Biosciences to Participate in Upcoming Investor Conferences

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that management will present and participate in the following investor conferences:

Yahoo | March 29, 2023

Here's Why 'Trend' Investors Would Love Betting on Tyra Biosciences, Inc. (TYRA)

Tyra Biosciences, Inc. (TYRA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Yahoo | March 27, 2023

Tyra Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the quarter and year ended December 31, 2022, and highlighted recent corporate progress.

Yahoo | March 22, 2023

Should You Buy Tyra Biosciences (TYRA) Ahead of Earnings?

Tyra Biosciences (TYRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Yahoo | March 1, 2023

Tyra Biosciences Expands Development of TYRA-300, an Oral FGFR3 Selective Agent, into Achondroplasia

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptors (FGFR) biology, today announced that it is expanding development of TYRA-300 into achondroplasia (ACH) based on positive preclinical results demonstrated in a study performed in collaboration with the Imagine Institute in Paris, France. Achondroplasia, the most common form of dwarfism, is a sk

Yahoo | March 1, 2023

Read More 'TYRA' Stories Here

TYRA Price Returns

1-mo 25.84%
3-mo 111.45%
6-mo 82.82%
1-year 50.19%
3-year N/A
5-year N/A
YTD 111.45%
2022 -45.98%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7452 seconds.